^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KRAS (KRAS proto-oncogene GTPase)

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    18h
    Correlation analysis between RAS gene mutations and pathological morphological features in colorectal cancer. (PubMed, Sci Rep)
    Histopathological evaluation may aid risk stratification alongside KRAS status. Prognostic assessment in clinical settings should take both TNM staging and KRAS status into account.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • NRAS mutation • PIK3CA mutation • KRAS G12D • KRAS wild-type • RAS mutation • RAS wild-type • KRAS G12 • NRAS G13
    1d
    Endometrial Carcinomas - Challenges and Updates on Selected Topics. (PubMed, Hum Pathol)
    Across these variants, integration of morphology with targeted immunohistochemistry and molecular testing (including p53, MMR status, POLE) is essential for accurate classification, risk stratification. HER2 overexpression and/or amplification occurs in 25-30% and HER2 testing has become a standard biomarker for selecting patients with recurrent or advanced disease for trastuzumab, and more recently trastuzumab-deruxtecan therapy.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    HER-2 overexpression • HER-2 amplification • ER negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    The current understanding of KRAS oligomerization on membranes. (PubMed, Curr Opin Struct Biol)
    In this perspective, we review the current understanding of KRAS oligomerization on membranes and its relevance for downstream signaling. Moreover, we discuss potential KRAS-KRAS interfaces, the effectors contributing to nanoclustering, such as the influence of the membrane lipid composition on KRAS nanoclustering, and outline the effect of small molecules on the RAS signaling pathway and nanoclustering.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    1d
    AND logic-gated CRISPR/Cas9 and hybridization chain reaction system for precise ctDNA detection. (PubMed, J Nanobiotechnology)
    Furthermore, we validated the specificity of our approach by successfully detecting various mutations, including KRAS G12C, KRAS G12D, EGFR T790M and TP53 R273H, in simulated clinical samples. These findings highlight a reliable method for precise ctDNA detection, offering high specificity, selectivity, and accuracy, thus paving the way for potential cancer diagnostic application.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • EGFR T790M • KRAS G12D • KRAS G12
    2d
    Transcriptomics analysis unveils the complex interplay between diabetes and hypertension in regulating renal cell carcinoma pathway followed by pancreatic metastasis. (PubMed, J Genet Eng Biotechnol)
    Mutational analysis further highlighted the significance of KRAS G12C, G12V, and G12D mutations, which were common between RCC and pancreatic metastasis. Our study provides critical insights into the statistically significant associations between metabolic disorders and malignancies, emphasizing the potential of tailored therapies alongside shared therapies in managing RCC and its progression to pancreatic metastasis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CDC42 (Cell Division Cycle 42) • MIR16 (MicroRNA 16) • MIR455 (MicroRNA 455)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12
    2d
    Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)
    This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)
    |
    TP53 mutation • SRSF2 mutation • STAT3 mutation
    2d
    E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study. (PubMed, ESMO Open)
    In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    TP53 mutation • KRAS mutation
    |
    E7386
    2d
    KontRASt-06: Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2027 --> Dec 2026
    Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12
    |
    opnurasib (JDQ443)
    2d
    Pearls and Pitfalls of Real-Life Molecular Testing on FNA and Core Biopsy in Pancreatic Adenocarcinoma Practice. (PubMed, Acta Cytol)
    Molecular testing is feasible and may even be more successful in cytologic smears than in biopsies or resections. High diagnostic yield and rapid processing favor their integration into routine molecular workflows. The superior performance of smears may relate to reduced stromal content and minimal processing delays. Cytologic specimens showed 100% DNA QC success, even when RNA QC failed, supporting their reliability. Although RNA analysis had a modest failure rate, its overall success suggests it can be incorporated into routine testing, particularly as fusion-driven targets gain clinical relevance.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • HRD (Homologous Recombination Deficiency)
    |
    KRAS mutation
    2d
    Molecular pathology of testicular germ cell tumours: an update for practicing pathologists. (PubMed, Histopathology)
    Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations...Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • MDM2 (E3 ubiquitin protein ligase) • AFP (Alpha-fetoprotein) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • KIT mutation • RAS mutation • KRAS G12
    |
    cisplatin
    3d
    A Review of Susceptibility Factors for Colibactin-Associated Colorectal Cancer in African Populations. (PubMed, Cureus)
    Consequently, this information may help reduce the rising rate of CRC in African populations through lifestyle modification and chemotherapy choices. To fully understand the complex interactions among environmental variables, genetic vulnerability, and colibactin-induced colorectal carcinogenesis in African populations, further investigation is necessary.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)